| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754398 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 7 Pages |
Abstract
There is a significant correlation between some markers, and certain ALL recurrent cytogenetic subgroups (CD123 and hyperdiploidy, CD79b negativity, and ETV-RUNX1 group) have good prognostic value. CD200 can be used as MRD markers in ALL patients and can also can serve as therapy targets.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Shady Adnan Awad, Mahmoud M. Kamel, Mahmoud A. Ayoub, Ahmed M. Kamel, Essam H. Elnoshokaty, Niveen El Hifnawi,